Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
C 86.99 1.16% 1.00
BPMC closed up 1.16 percent on Wednesday, August 4, 2021, on 56 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical BPMC trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
MACD Bullish Centerline Cross Bullish 0.00%
BB Squeeze Ended Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Fell Below 50 DMA Bearish 1.16%
Bollinger Band Squeeze Range Contraction 1.16%
NR7 Range Contraction 1.16%
Weak + Overbought Other 1.16%
Weak, Overbought and Reversal Signs Reversal 1.16%
Overbought Stochastic Strength 1.16%
Older End-of-Day Signals for BPMC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 18 hours ago
Rose Above Previous Day's High about 19 hours ago
Outside Day about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Up 1% about 19 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Blueprint Medicines Corporation Description

Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Gastrointestinal Cell Biology Genetic Disease Tyrosine Kinase Receptors Tyrosine Kinase Genetic Diseases Protein Kinase Inhibitor Cell Signaling Fibroblast Growth Factor Receptor Rare Genetic Disease Rare Genetic Diseases Gastrointestinal Stromal Tumor Mastocytosis Systemic Mastocytosis Myeloproliferative Neoplasm Receptor Tyrosine Kinase Mast Cell

Is BPMC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 125.61
52 Week Low 66.2
Average Volume 620,185
200-Day Moving Average 97.30
50-Day Moving Average 85.84
20-Day Moving Average 84.41
10-Day Moving Average 84.91
Average True Range 2.79
ADX 11.88
+DI 27.35
-DI 20.19
Chandelier Exit (Long, 3 ATRs) 81.04
Chandelier Exit (Short, 3 ATRs) 87.44
Upper Bollinger Bands 88.39
Lower Bollinger Band 80.43
Percent B (%b) 0.82
BandWidth 9.43
MACD Line 0.04
MACD Signal Line -0.48
MACD Histogram 0.5217
Fundamentals Value
Market Cap 4.85 Billion
Num Shares 55.7 Million
EPS 6.18
Price-to-Earnings (P/E) Ratio 14.08
Price-to-Sales 7.13
Price-to-Book 4.53
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 90.77
Resistance 3 (R3) 90.68 89.33 90.14
Resistance 2 (R2) 89.33 88.37 89.38 89.93
Resistance 1 (R1) 88.16 87.77 88.75 88.25 89.72
Pivot Point 86.81 86.81 87.10 86.86 86.81
Support 1 (S1) 85.64 85.85 86.23 85.73 84.26
Support 2 (S2) 84.29 85.25 84.34 84.05
Support 3 (S3) 83.12 84.29 83.84
Support 4 (S4) 83.21